Pre-treatment Ki67 index for everolimus efficacy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer: A multicenter cohort study

In a multicenter cohort study, data from 300 patients with HR+ HER2- advanced breast cancer were analyzed to explore the predictive value of the Ki67 index for everolimus efficacy. Results showed that the Ki67 cutoff value of 40% appeared to be the optimal index for improved progression free survival with everolimus.